ELI LILLY AND COMPANY v. HOSPIRA, INC.
Before Lourie, Moore, and Taranto. Appeal from the District Court for the Southern District of Indiana.
Summary: A narrowing claim amendment does not necessarily surrender all...more
REGENTS OF THE UNIV. OF MINN. v. LSI CORPORATION -
Before Dyk, Wallach, and Hughes. Appeal from the Patent Trial and Appeal Board.
Summary: State sovereign immunity does not apply to IPR proceedings asserted against...more
Federal Circuit Summary -
On September 10, 2018, the Federal Circuit decided Regents of the University of California v. Broad Institute, Inc., affirming the Patent Trial and Appeal Board (PTAB)’s determination of no...more
9/17/2018
/ Appeals ,
CRISPR ,
Interference Proceeding ,
Life Sciences ,
Obviousness ,
Patent Applications ,
Patent Infringement ,
Patent Trial and Appeal Board ,
Patents ,
Prior Art ,
Reaffirmation ,
Substantial Evidence Standard ,
University of California
Federal Circuit Summaries -
Before Reyna, Clevenger, and Wallach. Appeal from the United States District Court for the District of Colorado -
Summary: Even in a simple mechanical case, a narrow disclosure in the...more
Federal Circuit Summaries -
Before Newman, Dyk, and O’Malley. Appeal from the Patent Trial and Appeal Board.
Summary: The PTAB may enter an adverse judgment against a patent owner where, before issuing an institution...more
1/25/2018
/ Adverse Judgments ,
Appeals ,
Doctrine of Prosecution Disclaimer ,
Final Written Decisions ,
Inter Partes Review (IPR) Proceeding ,
Non-Appealable Decisions ,
Patent Owner Preliminary Response ,
Patent Trial and Appeal Board ,
Patents ,
Right To Appeal ,
Waivers
On August 30, 2017, the PTAB issued a Final Written Decision in M & P Golf, LLC (d/b/a Cool Clubs) v. Max Out Golf, LLC, IPR2016-00784, Paper 43 (P.T.A.B August 30, 2017), entering adverse judgement on the original patent...more
Janssen Biotech Inc. and Celltrion Healthcare have taken the next step over Janssen’s blockbuster arthritis biologic medicine Remicade (infliximab) and Celltrion’s biosimilar, as required by the Biologics Price Competition...more
7/1/2017
/ Biologics ,
Biosimilars ,
BPCIA ,
Celltrion ,
Good Faith ,
Janssen Pharmaceuticals ,
Lost Profits ,
Negotiations ,
Patent Dance ,
Patent Infringement ,
Patents ,
Pharmaceutical Industry ,
Pharmaceutical Patents
The PTAB issued a Final Written Decision in Amerigen Pharm. Ltd. v. Shire LLC, IPR2015-02009, Paper 38 (P.T.A.B. March 31, 2017) granting a rare motion to amend. The motion canceled all instituted claims and amended a...more
Written by Daniel A. Kamkar and Eric Furman, Ph.D. After the United Kingdom voted to leave the European Union, dubbed “Brexit” by the press, many have called into question whether the UK would ratify the Unitary Patent...more